{"id":"prednisolone-valerate-acetate","rwe":[{"pmid":"40497178","year":"2025","title":"Psoriatic Skin Lesions Induced by the Bacillus Calmette-Guerin (BCG) Vaccination in a Child With Latent Tuberculosis Infection: A Case Report.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"23373894","year":"2013","title":"Granuloma annulare-like reaction to the bacillus Calmette-Guerin vaccination.","finding":"","journal":"The Australasian journal of dermatology","studyType":"Clinical Study"}],"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Hormonal","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"acepreval","offLabel":[],"synonyms":["prednisolone valerate acetate","acepreval","prednisolone 17-valerate 21-acetate","prednisolone 21-acetate 17-valerate"],"timeline":[],"approvals":[],"brandName":"Acepreval","ecosystem":[],"mechanism":{"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"Imagine your body's immune response like a fire alarm that goes off when it senses danger. Acepreval helps turn down the volume on the alarm, reducing the inflammation and swelling that can cause harm. This allows the body to heal and recover from injury or illness.","oneSentence":"Acepreval works by binding to glucocorticoid receptors in the body, which then suppresses the production of inflammatory chemicals.","technicalDetail":"Acepreval, a prednisolone valerate acetate, exerts its anti-inflammatory effects by binding to glucocorticoid receptors, which then translocate to the nucleus and inhibit the transcription of pro-inflammatory genes, leading to a decrease in the production of inflammatory cytokines and mediators."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2252","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=prednisolone%20valerate%20acetate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prednisolone valerate acetate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:28:15.076913","biosimilars":[],"competitors":[],"genericName":"prednisolone valerate acetate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":["Lymphoblastic Leukemia, Acute","Lymphoblastic Leukemia, Acute, Childhood","Leukemia, Lymphoblastic, Acute, T Cell","Leukemia, Lymphoblastic, Acute"],"enrollment":6,"completionDate":"2012-01-10"},{"nctId":"NCT00186628","phase":"PHASE2","title":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-06","conditions":["Leukemia, Mast-Cell","Mantle-cell Lymphoma"],"enrollment":36,"completionDate":"2010-12"},{"nctId":"NCT01011621","phase":"PHASE3","title":"Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis","status":"UNKNOWN","sponsor":"Mantecorp Industria Quimica e Farmaceutica Ltd.","startDate":"2010-02","conditions":["Dermatitis, Atopic","Dermatitis, Contact","Dermatitis, Seborrheic","Psoriasis"],"enrollment":170,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"5347","NDDF":"002155","UNII":"2JB27QJW3D","CHEBI":"CHEBI:135785","VANDF":"4017988","INN_ID":"535","RXNORM":"8638","UMLSCUI":"C1882445","ChEMBL_ID":"CHEMBL1697848","KEGG_DRUG":"D03301","DRUGBANK_ID":"DB00860","PDB_CHEM_ID":" TUA","PUBCHEM_CID":"5284612","SNOMEDCT_US":"116601002","MESH_DESCRIPTOR_UI":"D011239","MESH_SUPPLEMENTAL_RECORD_UI":"C023724"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 May","pmid":"40497178","title":"Psoriatic Skin Lesions Induced by the Bacillus Calmette-Guerin (BCG) Vaccination in a Child With Latent Tuberculosis Infection: A Case Report.","journal":"Cureus"},{"date":"2013 Feb","pmid":"23373894","title":"Granuloma annulare-like reaction to the bacillus Calmette-Guerin vaccination.","journal":"The Australasian journal of dermatology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Acepreval (prednisolone valerate acetate) is a corticosteroid small molecule medication. It works by suppressing the immune system to reduce inflammation and swelling. However, due to the lack of available information, its target, FDA approval status, and commercial status are unknown. Acepreval is used to treat various conditions, but specific indications are not provided. As a corticosteroid, it carries key safety considerations, including potential side effects on the adrenal glands and increased risk of infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}